Professors Anna Martling and Ulf Hedin, both at MMK, are new members of the Board of Directors at CIMED

Published 2017-08-15 13:28. Updated 2017-08-15 13:29Denna sida på svenska

CIMED, the Center for Innovative Medicine, is changing its focus and have a new board starting from 1 July 2017. In addition to the new board with a greater clinical competence, CIMED is to focus more on supporting clinical research than previously. Research on chronic diseases and diseases with a heavy disease burden will also have a high priority.

CIMED, whose objective is to find new treatments for endemic diseases, was inaugurated in 2015 and is funded primarily by SLL, but is a part of KI’s organization. SLL has now reviewed the support it provides to CIMED, which amounts to SEK 81 million annually. 

CIMED’s new board

Peter Lönnroth, professor, chair
Lars I Eriksson, professor, SLL
Anna Martling, professor, SLL
Annika Tibell, professor, SLL
Karin Dahlman-Wright, professor, KI
Ulf Hedin, professor, KI
Peter Stenvinkel, professor, KI

Read more about CIMED at: cimed.ki.se